Focus Partners Wealth
CTKB icon

Focus Partners Wealth’s Cytek Biosciences CTKB Stock Holding History

Focus Partners Wealth’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Sell
28,205
-5,472
-16% -$23.4K ﹤0.01% 2585
2026
Q1 		$147K Buy
33,677
+180
+0.5% +$850 ﹤0.01% 2465
2025
Q4 		$169K Sell
33,497
-37,079
-53% -$172K ﹤0.01% 2474
2025
Q3 		$31.2M Buy
+70,576
New +$265K 0.05% 299

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Focus Partners Wealth's CTKB Position: Q2 2026 in Review

Focus Partners Wealth reduced its Cytek Biosciences (CTKB) stake by 16% in Q2 2026, selling an estimated $23.4K and leaving 28,205 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #2585.

Focus Partners Wealth first reported a position in CTKB in Q3 2025 and has held it in 4 quarters since. The position peaked at $31.2M in Q3 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Focus Partners Wealth held 28,205 shares of Cytek Biosciences worth $125K as of Q2 2026.
  • Focus Partners Wealth sold 5,472 Cytek Biosciences shares in Q2 2026, an estimated $23.4K.
  • Cytek Biosciences made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2585 holding.
  • Focus Partners Wealth first reported a position in Cytek Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Focus Partners Wealth's Cytek Biosciences position peaked at $31.2M in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.